Status:
COMPLETED
Assessing and Promoting Resilience in Patients With Adult Congenital Heart Disease
Lead Sponsor:
University of Washington
Collaborating Sponsors:
National Heart, Lung, and Blood Institute (NHLBI)
Conditions:
Congenital Heart Disease
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The purpose of this study is to evaluate the feasibility and preliminary efficacy of the Promoting Resilience in Stress Management (PRISM) intervention in patients with adult congenital heart disease.
Detailed Description
After consent is obtained, eligible patients (moderate or complex ACHD, stages B, C, or D) will complete the baseline study measures assessment and be randomized to receive PRISM or usual care (antici...
Eligibility Criteria
Inclusion
- adults with moderate or complex ACHD, stages B, C, or D as defined by the 2018 ACHD guidelines
- receive care in our health system
Exclusion
- diagnosis of another life-limiting illness
- inability to participate in study activities independently and in English
Key Trial Info
Start Date :
March 15 2023
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 25 2024
Estimated Enrollment :
78 Patients enrolled
Trial Details
Trial ID
NCT04738474
Start Date
March 15 2023
End Date
July 25 2024
Last Update
December 15 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Washington
Seattle, Washington, United States, 98195